Executive Summary
•Assaí trades at 7.5x NTM P/E and 4.8x NTM EV/EBITDA, a 47 to 56% discount to its own two year average, pricing in a deep consumer recession that has not yet appeared in traffic: customer flow +3.4% YoY, market share +0.3pp.
•Same store sales +2.4% with July running +0.5%, held up by frequency rather than ticket, as trade down of roughly 2% caps basket size and food inflation stays out of the average purchase.
•Deleveraging is the swing factor: net debt/EBITDA at 2.37x, financial expense down 25% YoY, recurring net income BRL 241m against a thin 1.2% net margin.
•Optionality from Assai Pharma, private label mix and Extra conversion maturation is not in the multiple; a re rating to 9 to 10x NTM P/E alone implies $12 to $14.
Financial Snapshot
•Revenue TTM: $77.57b
•Revenue growth NTM consensus: +5.2%
•Gross margin: 18.2%
•Operating margin: 7.1%
•Net margin: 1.2%
•ROE: 16.2%
•Debt/Equity: 425.4%
•Net debt/EBITDA: 2.37x
•Forward EPS NTM: $1.06
•Forward EPS growth: +2.6%
•Q4 revenue: $19.18b, net income $0.48b
•Q3 revenue: $18.64b, net income $0.32b
•Q2 revenue: $20.80b, net income $0.01b
•Q1 revenue: $18.96b, net income $0.15b
Forward Outlook
•NTM revenue $79.64b (+5.2% YoY), FY+2 revenue $83.78b
•NTM EPS $1.06, FY+2 EPS $1.09, implying only +2.6% earnings growth
•Same store sales guided to roughly plus or minus 1pp around flat, with July at +0.5%
•Gross margin defended via private label mix and supplier negotiation, with a 0.26pp tax substitution drag normalising out
•SG&A per customer served running 1.6% below food and headline inflation, the core operating leverage story
•Net debt/EBITDA trending down from 2.37x as gross debt falls and average cost of debt drops
•Assai Pharma and private label flagged as the next growth avenues, contribution economics not disclosed
Valuation Analysis
•NTM P/E: 7.5x
•NTM P/S: 0.13x
•NTM EV/EBITDA: 4.8x
•NTM EV/EBIT: 7.3x
•NTM EV/Rev: 0.4x
•LF P/BV: 1.7x
•Two year average P/E: 16.9x, so 7.4x is -56% vs history
•Two year average EV/EBITDA: 8.9x, so 4.8x is -47% vs history
•Two year average EV/EBIT: 12.9x, so 7.3x is -43% vs history
•Two year average EV/Rev: 0.8x, so 0.4x is -47% vs history
•Two year average P/BV: 5.2x, so 1.7x is -67% vs history
•Implied price at historical average P/E: $18.35
•Implied price at historical average EV/EBITDA: $29.83
•Implied price at historical average EV/EBIT: $27.01
•Implied price at historical average EV/Rev: $30.51
•Implied price at historical average P/BV: $24.46
•52 week range: $6.91 to $14.23
•Base case fair value: $12 to $14, a re rating to 9 to 10x NTM P/E
•Bull case fair value: $18 to $20, partial reversion toward historical multiples
•Bear case fair value: $7, multiple stays depressed on flat earnings
•PCAR3.SA: negative forward P/E, loss making, MC $1.1b, direct cash and carry competitor
•GMAT3.SA: 5.2x TTM P/E, MC $8.8b, food retail peer trading at a similar trough multiple
•Peer set confirms the whole Brazilian food retail complex is de rated, so re rating needs an earnings catalyst, not just sentiment
Key Risks & Catalysts
Risks
•Consumer trade down of roughly 2% and Class C/D income pressure capping average ticket
•High Brazilian interest rates keeping financial expense elevated despite the 25% YoY reduction
•ICMS and tax substitution changes distorting gross versus net sales and gross margin optics
•Leverage at 2.37x net debt/EBITDA with Debt/Equity of 425.4% leaves limited balance sheet cushion
•Net margin of 1.2% means small revenue misses swing earnings hard
•BRL volatility and imported food cost inflation pressuring gross margin
•Competitive intensity across cash and carry limiting price and mix flexibility
Catalysts
•Net debt/EBITDA breaking below 2.0x, which would de risk the equity story
•Assai Pharma rollout beyond the first Sao Paulo store, adding a higher margin category
•Private label mix shift lifting gross margin above the current 18.2%
•Extra hypermarket conversion stores maturing into full sales density
•A Selic cutting cycle lowering the cost of debt and freeing consumer income
•Same store sales inflecting back above 2% on easier comparatives
•MercadoLibre marketplace partnership expanding the addressable channel
Investment Thesis
Assaí is a high quality operator stuck in a low quality macro. The business is executing: traffic +3.4%, share +0.3pp, SG&A per customer 1.6% below inflation, and leverage down to 2.37x. None of that is being rewarded. At 7.5x NTM P/E and 4.8x NTM EV/EBITDA the market is pricing a consumer that is already in recession, yet same store sales are still positive at +2.4% with July at +0.5%. The gap between operating reality and valuation is the entire thesis.
The earnings engine is deleveraging, not top line. With a 1.2% net margin, every real of financial expense saved drops almost straight to the bottom line, and financial expense is already down 25% YoY. Consensus models only +2.6% EPS growth, which looks too conservative if the cost of debt keeps falling and the Extra conversion cohort keeps maturing. That combination is what turns a 7.5x multiple into a 9 to 10x multiple without needing a demand recovery.
Buy at $8.00 with a base case fair value of $12 to $14, a re rating to 9 to 10x NTM P/E on visible deleveraging. The bull case at $18 to $20 requires a Selic cutting cycle plus Assai Pharma and private label contributing, while the bear case at $7 assumes flat earnings and a permanently de rated multiple. Risk is skewed to the upside on a 12 to 18 month view, with the main threat being a deeper for longer consumer squeeze that keeps the ticket under pressure.
